Stratus Therapeutics Revenue

Biotechnology Research • United States • 51-100 Employees

Stratus Therapeutics revenue & valuation

Annual revenue	$4,448,860
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$14,300,000
Total funding	$50,000,000

Key Contacts at Stratus Therapeutics

Gustavo Rodriguez

Director Of Quality Control

Avanish Vellanki

President & Chief Executive Officer

Sarah Myers

Director, Head Of People & Culture

Luis Escobar

Associate Director Quality Assurance

Eric Strait

Sr. Director, Legal Affairs

Bryan Dumont

Director Clinical Operations

Ruchi Shah

Director Of Quality Assurance

David Scadden

Co-Founder, Co-Chair Sab

Jack Jie

Director

Hector Ocasio

Sr Director Operations And Supply Chain

Company overview

Headquarters	United States
Website	stratustx.com
NAICS	541714
Employees	51-100
Socials

Stratus Therapeutics Email Formats

Stratus Therapeutics uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@stratustx.com), used 59.5% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@stratustx.com	59.5%
{first initial}.{last name}	j.doe@stratustx.com	40.5%

About Stratus Therapeutics

Stratus Therapeutics is redefining regenerative medicine with Stratus Prime™ — a platform for full hematopoietic system renewal, on demand. Our proprietary product, ST-101, includes both hematopoietic stem cells (Prime HSCs™) and hematopoietic progenitor cells (Prime HPCs™) to drive durable, long-term engraftment with full hematopoietic system restoration, while supporting near-term immune reconstitution. ST-101 is uniquely engineered to deliver a high proportion of Prime HSCs™ in the absence of T-cells, positioning it as a next-generation allogeneic graft, but with immediate availability. ST-101 aims to offer enhanced engraftment outcomes while reducing the risk of graft-versus-host disease (GvHD). As an off-the-shelf therapy with full HLA immune compatibility, ST-101 aims to eliminate the search associated with finding donors and potentially mitigate the challenges of conventional conditioning regimens. Stratus Therapeutics hopes to position ST-101 as a scalable path to curative blood and immune system replacement.

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Senior

Director

Entry

Employees by Department

Stratus Therapeutics has 19 employees across 9 departments.

Departments

Number of employees

Funding Data

Explore Stratus Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2025-04-04	4	$50,000,000

Funding Insights

$50,000,000

Total funding amount

$50,000,000

Most recent funding amount

Number of funding rounds

Frequently asked questions

Stratus Therapeutics is located in US.

Stratus Therapeutics generates an estimated annual revenue of $4,448,860. This revenue figure reflects the company's market position and business performance in its industry.

Stratus Therapeutics has an estimated valuation of $14,300,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Stratus Therapeutics has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.

Stratus Therapeutics has raised a total of $50,000,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.